Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$68.93 USD
+0.18 (0.26%)
Updated Sep 4, 2024 04:00 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
- YR Estimate
- 12/31/2023
- 12/31/2022
- 12/31/2021
- 12/31/2020
- 12/31/2019
- Revenue - Line of Business (LOBR)
- Net Sales: Transcatheter Aortic Valve Replacement
- 3,879.80
- 3,518.20
- 3,422.50
- 2,857.30
- 2,737.90
- Revenue - Line of Business (LOBR)
- Net Sales: Transcatheter Mitral and Tricuspid Therapies
- 197.60
- 116.10
- 86.00
- 41.80
- 28.20
- Revenue - Line of Business (LOBR)
- Net Sales: Surgical Structural Heart
- 999.30
- 893.10
- 889.10
- 761.80
- 841.70
- Revenue - Line of Business (LOBR)
- Net Sales: Critical Care
- 928.10
- 855.00
- 834.90
- 725.40
- 740.20
- Revenue - Geographic (GEOR)
- Net Sales: United States
- 3,508.70
- 3,132.60
- 2,963.10
- 2,516.80
- 2,532.70
- Revenue - Geographic (GEOR)
- Net Sales: Outside of the United States
- 2,496.10
- 2,249.80
- 2,269.40
- 1,869.50
- 1,815.30
- Revenue - Geographic (GEOR)
- Net Sales: Europe
- 1,334.50
- 1,174.80
- 1,190.30
- 973.60
- 941.20
- Revenue - Geographic (GEOR)
- Net Sales: Japan
- 452.40
- 473.60
- 528.90
- 460.10
- 444.70
- Revenue - Geographic (GEOR)
- Net Sales: Rest of World
- 709.20
- 601.40
- 550.20
- 435.80
- 433.30